„Off-label use“ in der Herzchirurgie

In the view of off-label use, special concern should be granted to obtaining informed consent from the patient. It is important to point out the test character of the treatment. The patient has to be informed about the risks that exist with the treatment. The patient has to know that a drug not yet...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenger, H., Löher, A., Sindermann, J.R., Scheld, H.H., Schmidt, C., Hoffmeier, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Das medicolegale Thema
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102367/
https://www.ncbi.nlm.nih.gov/pubmed/32288286
http://dx.doi.org/10.1007/s00398-009-0732-y
_version_ 1783511809281490944
author Fenger, H.
Löher, A.
Sindermann, J.R.
Scheld, H.H.
Schmidt, C.
Hoffmeier, A.
author_facet Fenger, H.
Löher, A.
Sindermann, J.R.
Scheld, H.H.
Schmidt, C.
Hoffmeier, A.
author_sort Fenger, H.
collection PubMed
description In the view of off-label use, special concern should be granted to obtaining informed consent from the patient. It is important to point out the test character of the treatment. The patient has to be informed about the risks that exist with the treatment. The patient has to know that a drug not yet approved for this treatment is being used and the risks linked with its use have to be addressed. In addition, informed consent has to be documented and the differences compared with the standard treatment have to be pointed out.
format Online
Article
Text
id pubmed-7102367
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-71023672020-03-31 „Off-label use“ in der Herzchirurgie Fenger, H. Löher, A. Sindermann, J.R. Scheld, H.H. Schmidt, C. Hoffmeier, A. Z Herz Thorax Gefasschir Das medicolegale Thema In the view of off-label use, special concern should be granted to obtaining informed consent from the patient. It is important to point out the test character of the treatment. The patient has to be informed about the risks that exist with the treatment. The patient has to know that a drug not yet approved for this treatment is being used and the risks linked with its use have to be addressed. In addition, informed consent has to be documented and the differences compared with the standard treatment have to be pointed out. Springer-Verlag 2009-07-22 2009 /pmc/articles/PMC7102367/ /pubmed/32288286 http://dx.doi.org/10.1007/s00398-009-0732-y Text en © Springer-Verlag 2009 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Das medicolegale Thema
Fenger, H.
Löher, A.
Sindermann, J.R.
Scheld, H.H.
Schmidt, C.
Hoffmeier, A.
„Off-label use“ in der Herzchirurgie
title „Off-label use“ in der Herzchirurgie
title_full „Off-label use“ in der Herzchirurgie
title_fullStr „Off-label use“ in der Herzchirurgie
title_full_unstemmed „Off-label use“ in der Herzchirurgie
title_short „Off-label use“ in der Herzchirurgie
title_sort „off-label use“ in der herzchirurgie
topic Das medicolegale Thema
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102367/
https://www.ncbi.nlm.nih.gov/pubmed/32288286
http://dx.doi.org/10.1007/s00398-009-0732-y
work_keys_str_mv AT fengerh offlabeluseinderherzchirurgie
AT lohera offlabeluseinderherzchirurgie
AT sindermannjr offlabeluseinderherzchirurgie
AT scheldhh offlabeluseinderherzchirurgie
AT schmidtc offlabeluseinderherzchirurgie
AT hoffmeiera offlabeluseinderherzchirurgie

Ejemplares similares